Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species
The present invention relates to the use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species.
1. A method of treating a subject having an increased intracranial pressure, comprising administering to the subject a therapeutically sufficient amount of a compound of the general formula (Ia)
wherein in formula (Ia) R 1 , R 3 are independently selected from H or OH, R 4 is H, CH 3 , CH 2 OH; CHO, R 2 is H, CH 3 , CH 2 OH, CHO or a lower C 1 -C 9 alkyl radical, which can be a straight or a branched chain, as well as (CH(OH)) n —Y or (CH(OH)) n —(CH 2 ) m —W, wherein Y is hydrogen or a lower alkyl radical, W is hydrogen or a hydroxyl group, an n and m are independently from each other 1-20,
wherein the increased intracranial pressure is caused by closed craniocerebral trauma.
2. A method of claim 1 , wherein R 1 and R 4 in formula (Ia) are hydrogen, R 2 is methyl and R 3 is hydroxyl.
3. A method of claim 2 , wherein the compound is 2,4-diamino-5,6,7,8-tetrahydro-6-(L-erythro-1,2-dihydroxypropyl)-pteridine.
4. The method of claim 1 , wherein the subject is a mammal.
5. The method of claim 4 , wherein the subject is a human.